Novel Induction Regimens in Multiple Myeloma.
Multiple myeloma is the second most common hematologic malignancy and predominantly affects the elderly. The introduction of novel agents such as thalidomide, lenalidomide, and bortezomib has improved progression-free survival, overall survival, and quality of life in myeloma patients. Next generation agents such as carfilzomib hold further promise for increased depth and length of remission. Autologous stem cell transplant remains a useful tool in the treatment of multiple myeloma, but not all patients are eligible for this procedure. As therapy becomes more effective, determination of the right therapy in the right patient becomes paramount. The focus of this review is a critical analysis of combinations of the novel agents in the treatment of newly diagnosed multiple myeloma in both transplant eligible and ineligible patients.
Department of Medicine, Division of Hematology/Oncology, Weill Cornell Medical College, New York, NY, USA. kdr9003@nyp.org.|Department of Medicine, New York Presbyterian Hospital-Cornell Medical Center, 525 East 68th Street, New York, NY, 10021, USA. kdr9003@nyp.org.
Karie D
KD
Runcie
Department of Medicine, Division of Hematology/Oncology, Weill Cornell Medical College, New York, NY, USA. tom9009@med.cornell.edu.|Weill Cornell Medical College, Center for Myeloma, 428 E. 72nd street, Suite 300, New York, NY, 10021, USA. tom9009@med.cornell.edu.
Tomer M
TM
Mark
D006801:Humans; D060828:Induction Chemotherapy / Q000379:methods*; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000601:surgery; D019737:Transplants
Induction; Multiple myeloma; Novel agents; Transplant eligible; Transplant ineligible